The subcutaneous formulation of nivolumab showed noninferiority to intravenous administration in efficacy and safety for advanced or metastatic clear cell renal cell carcinoma. The European Commission ...

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant nivolumab in patients with bladder cancer. Targeted Oncology: What was the ...

Expanding a customer base is crucial for businesses to maintain long-term growth, remain competitive and adapt to changing market dynamics. Without a strategic, well-defined approach, companies ...

Eighty percent of patients achieved a clinical complete response. Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient (dMMR), surgically resectable ...